Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
This study is evaluating the addition of ART6043, a novel targeted therapy, to olaparib, a standard treatment, in adults with HER2-negative advanced or metastatic breast cancer and an inherited germline BRCA mutation.
This study compares talazoparib with or without Enzalutamide in patients with metastatic castration-resistant prostate cancer and an HRR mutation after progression on Abiraterone Acetate or Darolutamide
ERADICATE: Hormone and Targeted Therapy for HR+/HER2-Low Advanced Breast Cancer
The study is for people with hormone receptor-positive (HR+), HER2-low or HER2-ultralow breast cancer that has spread to other parts of the body (metastatic) or is locally advanced and cannot be removed with surgery.
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Topic : Inherited BRCA mutations may affect CDK4/6 treatment outcomes
Several studies suggest that people with an inherited BRCA1 or BRCA2 mutation and hormone receptor-positive, HER2-negative breast cancer may have a shorter response to CDK4/6 inhibitors than people without these mutations. (posted 10/21/2026)
Study : Genetic testing can help identify who needs high-risk breast screening
Researchers in the WISDOM Study looked at women who had genetic testing and had an inherited mutation in a gene linked to increased breast cancer risk. When only risk factors other than genetic testing were...
Update : FDA approves Truqap for some people with metastatic prostate cancer
The Food and Drug Administration (FDA) approved Truqap (capivasertib) with abiraterone and prednisone for adults with metastatic prostate cancer that still responds to hormone-lowering treatment but is missing a protein called PTEN. This approval provides...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.